All eyes on sales momentum for Eli Lilly's obesity drug Zepbound
Pharmaceutical giant Eli Lilly (LLY:NYSE) is due to report first-quarter earnings before the market opens on 30 April. Wall Street is expecting EPS (earnings per share) of $2.54 which represents a 57% increase compared with the first quarter of 2023.All eyes will be on sales momentum in Lilly?s diabetes treatment Mounjaro and obesity treatment Zepbound following the latter?s launch in November 202